

2026

Step Therapy Criteria

Last Updated: 04/21/2026

HPMS Approved Formulary File Submission ID 00026417, Version Number 21

ICS/LABA/LAMA

Products Affected

- TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT INHALATION
- TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 200-62.5-25 MCG/ACT INHALATION

Details

Criteria	
	Trial of a LABA or LAMA containing product

Topical PDE-4 Inhibitors

Products Affected

- EUCRISA OINTMENT 2 % EXTERNAL

Details

Criteria	Trial of topical corticosteroid
-----------------	---------------------------------

Index

EUCRISA OINTMENT 2 % EXTERNAL..12
TRELEGY ELLIPTA AEROSOL
POWDER BREATH ACTIVATED 100-
62.5-25 MCG/ACT INHALATION..... 11
TRELEGY ELLIPTA AEROSOL
POWDER BREATH ACTIVATED 200-
62.5-25 MCG/ACT INHALATION..... 11